HUE061770T2 - 1H-pirrolo[2,3-C]piridin-7(6H)-onok és pirazolo[3,4-C]piridin-7(6H)-onok mint BET fehérjék gátlószerei - Google Patents

1H-pirrolo[2,3-C]piridin-7(6H)-onok és pirazolo[3,4-C]piridin-7(6H)-onok mint BET fehérjék gátlószerei

Info

Publication number
HUE061770T2
HUE061770T2 HUE20156599A HUE20156599A HUE061770T2 HU E061770 T2 HUE061770 T2 HU E061770T2 HU E20156599 A HUE20156599 A HU E20156599A HU E20156599 A HUE20156599 A HU E20156599A HU E061770 T2 HUE061770 T2 HU E061770T2
Authority
HU
Hungary
Prior art keywords
pyridin
ones
pyrazolo
pyrrolo
inhibitors
Prior art date
Application number
HUE20156599A
Other languages
English (en)
Hungarian (hu)
Inventor
Andrew Combs
Thomas Maduskuie
Nikoo Falahatpisheh
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53055117&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE061770(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Publication of HUE061770T2 publication Critical patent/HUE061770T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
HUE20156599A 2014-04-23 2015-04-22 1H-pirrolo[2,3-C]piridin-7(6H)-onok és pirazolo[3,4-C]piridin-7(6H)-onok mint BET fehérjék gátlószerei HUE061770T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983289P 2014-04-23 2014-04-23

Publications (1)

Publication Number Publication Date
HUE061770T2 true HUE061770T2 (hu) 2023-08-28

Family

ID=53055117

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE20156599A HUE061770T2 (hu) 2014-04-23 2015-04-22 1H-pirrolo[2,3-C]piridin-7(6H)-onok és pirazolo[3,4-C]piridin-7(6H)-onok mint BET fehérjék gátlószerei
HUE15721085A HUE049627T2 (hu) 2014-04-23 2015-04-22 1H-pirrolo[2,3-C]piridin-7(6H)-onok és pirazolo[3,4-C]piridin-7(6H)-onok, mint BET fehérjék inhibitorai

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE15721085A HUE049627T2 (hu) 2014-04-23 2015-04-22 1H-pirrolo[2,3-C]piridin-7(6H)-onok és pirazolo[3,4-C]piridin-7(6H)-onok, mint BET fehérjék inhibitorai

Country Status (38)

Country Link
US (8) US9540368B2 (OSRAM)
EP (3) EP3674302B1 (OSRAM)
JP (2) JP6572237B2 (OSRAM)
KR (3) KR102702503B1 (OSRAM)
CN (1) CN106414442B (OSRAM)
AR (1) AR100160A1 (OSRAM)
AU (3) AU2015249810B2 (OSRAM)
BR (1) BR112016024626B1 (OSRAM)
CA (1) CA2946731C (OSRAM)
CL (1) CL2016002681A1 (OSRAM)
CR (2) CR20200231A (OSRAM)
CY (2) CY1122948T1 (OSRAM)
DK (2) DK3134403T3 (OSRAM)
EA (2) EA039678B1 (OSRAM)
EC (1) ECSP16088983A (OSRAM)
ES (2) ES2942723T3 (OSRAM)
FI (1) FI3674302T3 (OSRAM)
HR (2) HRP20230340T1 (OSRAM)
HU (2) HUE061770T2 (OSRAM)
IL (3) IL248415B (OSRAM)
LT (2) LT3134403T (OSRAM)
MA (1) MA39985B1 (OSRAM)
ME (1) ME03763B (OSRAM)
MX (2) MX376174B (OSRAM)
MY (3) MY180775A (OSRAM)
NZ (3) NZ763737A (OSRAM)
PE (1) PE20170144A1 (OSRAM)
PH (1) PH12016502115B1 (OSRAM)
PL (2) PL3134403T3 (OSRAM)
PT (2) PT3134403T (OSRAM)
RS (2) RS64231B1 (OSRAM)
SG (2) SG10201809353TA (OSRAM)
SI (2) SI3134403T1 (OSRAM)
SM (2) SMT202000133T1 (OSRAM)
TW (2) TWI672301B (OSRAM)
UA (1) UA119870C2 (OSRAM)
WO (1) WO2015164480A1 (OSRAM)
ZA (1) ZA202101718B (OSRAM)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
KR102702503B1 (ko) 2014-04-23 2024-09-05 인사이트 홀딩스 코포레이션 BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
WO2016044130A1 (en) 2014-09-15 2016-03-24 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
MA40940A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
WO2016077375A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Bromodomain inhibitors and uses thereof
CN107531692B (zh) 2015-01-29 2020-12-25 基因泰克公司 治疗化合物及其用途
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
AU2016305513A1 (en) 2015-08-11 2018-03-08 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
WO2017024406A1 (en) * 2015-08-11 2017-02-16 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
JP6912039B2 (ja) 2015-08-12 2021-07-28 ネオメド インスティテュートＮｅｏｍｅｄ Ｉｎｓｔｉｔｕｔｅ 置換ベンゾイミダゾール、それらの調製及び医薬品としてのそれらの使用
US10501459B2 (en) 2015-10-21 2019-12-10 Neomed Institute Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
US10519151B2 (en) 2016-01-28 2019-12-31 Neomed Institute Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
CA3018802A1 (en) 2016-04-15 2017-10-19 Abbvie Inc. Bromodomain inhibitors
PH12021551886A1 (en) 2016-06-20 2023-07-17 Incyte Corp Crystalline solid forms of a bet inhibitor
EP3539960A4 (en) 2016-11-10 2020-03-18 Luoxin Pharmaceutical (Shanghai) Co., Ltd. NITROGEN MACROCYCLIC COMPOUND, ITS PREPARATION METHOD, ITS PHARMACEUTICAL COMPOSITION AND ITS APPLICATION
TW201825490A (zh) * 2017-01-11 2018-07-16 大陸商江蘇豪森藥業集團有限公司 吡咯並［２，３－ｃ］吡啶類衍生物、其製備方法及其在醫藥上的應用
MX2020000690A (es) 2017-07-18 2020-07-29 Nuvation Bio Inc Compuestos heterociclicos como antagonistas de adenosina.
BR112020000962A2 (pt) 2017-07-18 2020-07-14 Nuvation Bio Inc. compostos de 1,8-naftiridinona e usos dos mesmos
US11180510B2 (en) 2017-11-06 2021-11-23 Centre National De La Recherche Scientifique Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins
MX2020006612A (es) * 2017-12-20 2020-11-09 Betta Pharmaceuticals Co Ltd Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
EP3728207B1 (en) 2017-12-21 2023-02-01 Ribon Therapeutics Inc. Quinazolinones as parp14 inhibitors
CA3090439A1 (en) * 2018-02-06 2019-08-15 Shanghai Haihe Pharmaceutical Co., Ltd. Compound having bet inhibitory activity and preparation method and use therefor
CN110776508B (zh) 2018-07-27 2021-07-16 海创药业股份有限公司 一种brd4抑制剂及其制备方法和用途
CN109580433B (zh) * 2018-10-26 2021-05-28 中国辐射防护研究院 一种常规爆炸放射性气溶胶扩散的源项估算方法
AU2019372121A1 (en) 2018-10-30 2021-05-27 Nuvation Bio Inc. Heterocyclic compounds as BET inhibitors
CN109432093A (zh) * 2018-12-23 2019-03-08 黄泳华 由吡唑并吡啶酮类化合物构成的乙酰胆碱酯酶抑制剂的增效体系
EP3911323A4 (en) 2019-01-18 2022-11-16 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
CA3126931A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
BR112021018372A2 (pt) * 2019-03-17 2021-11-23 Shanghai Ringene Biopharma Co Ltd Composto acilaminopirrolo-piridona, método para preparar o referido composto, composição farmacêutica e uso do mesmo
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
CN110003204B (zh) * 2019-04-30 2020-08-11 上海勋和医药科技有限公司 一种bet蛋白抑制剂、其制备方法及用途
CN112094266B (zh) * 2019-06-17 2023-03-21 中国科学院上海药物研究所 一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途
CN114206853A (zh) * 2019-06-19 2022-03-18 里邦医疗公司 用于治疗的parp14的靶向蛋白质降解
KR102677015B1 (ko) 2019-07-02 2024-06-19 누베이션 바이오 인크. Bet 억제제로서의 헤테로시클릭 화합물
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
PE20221283A1 (es) 2019-12-27 2022-09-05 Lupin Ltd Compuestos triciclicos sustituidos
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CA3184633A1 (en) * 2020-06-03 2021-12-09 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022116968A1 (zh) 2020-12-01 2022-06-09 成都苑东生物制药股份有限公司 一种新型n-杂环bet溴结构域抑制剂、其制备方法及医药用途
WO2022132049A1 (en) * 2020-12-17 2022-06-23 National University Of Singapore Treating cancers using bet inhibitors
US20240366608A1 (en) 2021-01-19 2024-11-07 Lupin Limited Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer
GB2641636A (en) * 2022-12-23 2025-12-10 Tay Therapeutics Ltd Selective BET inhibitors and uses thereof

Family Cites Families (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2404E (fr) 1899-12-05 1904-03-26 Louis Olivier Victor Parmentie Machine à copier les lettres
JPS59170313A (ja) 1983-03-14 1984-09-26 Kurimoto Iron Works Ltd スクリ−ンゲ−ト
JPS6053449A (ja) 1983-09-01 1985-03-27 M K Seikou Kk 洗車機
JPS6085739U (ja) 1983-11-18 1985-06-13 クラリオン株式会社 テ−プレコ−ダにおけるピンチロ−ラ装置
JPS6243003U (OSRAM) 1985-09-05 1987-03-14
JPH0314566A (ja) 1989-06-09 1991-01-23 Sankyo Co Ltd ベンズイミダゾール誘導体
US5244912A (en) 1991-03-28 1993-09-14 Eli Lilly And Company 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof
FR2710915B1 (fr) 1993-10-04 1995-11-24 Synthelabo Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique.
GB9410469D0 (en) 1994-05-25 1994-07-13 Erba Farmitalia Imidazolylalkyl derivatives of imidazo (5,1-c) (1,4) benzoxazin-1-one and process for their preparation
FR2731708B1 (fr) 1995-03-13 1997-04-30 Synthelabo Derives de piperidine, leur procede de preparation et leur application en therapeutique
FR2747678B1 (fr) 1996-04-22 1998-05-22 Synthelabo Composes derives d'imidazobenzoxazine, leurs procedes de preparation et leurs utilisations en therapeutique
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
CA2405565A1 (en) 2000-04-21 2001-11-01 Pharmacia & Upjohn Company Compounds for treating fibromyalgia and chronic fatigue syndrome
JP4188078B2 (ja) 2000-06-28 2008-11-26 スミスクライン ビーチャム ピー エル シー 湿式粉砕法
CZ294493B6 (cs) 2000-08-08 2005-01-12 Sanofi-Synthelabo Deriváty benzimidazolu, způsob jejich přípravy a léčebné prostředky s jejich obsahem
FR2816619B1 (fr) 2000-11-15 2003-01-31 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
US6919334B2 (en) 2002-09-12 2005-07-19 Wyeth Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine
RU2342388C2 (ru) 2002-11-22 2008-12-27 Джапан Тобакко Инк. Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием
EP1462103A1 (en) 2003-03-25 2004-09-29 Faust Pharmaceuticals NO donors, combination products and uses as modulators of neurotransmitter release
AU2005214258A1 (en) 2004-02-23 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. Novel heterocyclic compound
JP4790703B2 (ja) 2004-04-07 2011-10-12 武田薬品工業株式会社 環式化合物
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
DE102005011058A1 (de) 2005-03-10 2006-09-14 Merck Patent Gmbh Substituierte Tetrahydro-pyrrolo-chinolinderivate
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2006129623A1 (ja) 2005-05-30 2006-12-07 Mitsubishi Tanabe Pharma Corporation チエノトリアゾロジアゼピン化合物及びその医薬としての用途
US20080318999A1 (en) 2005-08-05 2008-12-25 Methvin Isaac Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators
US8975259B2 (en) 2007-04-27 2015-03-10 University Of Rochester Compositions and methods for inhibiting G protein signaling
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
WO2009020559A2 (en) 2007-08-03 2009-02-12 The J. David Gladstone Institutes Agents that inhibit p-tefb interactions and methods of use thereof
JP5478262B2 (ja) 2007-12-28 2014-04-23 田辺三菱製薬株式会社 抗癌剤
DE102008052618A1 (de) 2008-10-21 2010-04-22 Henkel Ag & Co. Kgaa Tricyclische Aldehyde und C,H-acide Verbindungen
WO2010111626A2 (en) 2009-03-27 2010-09-30 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
TW201103941A (en) 2009-06-10 2011-02-01 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
TW201105681A (en) 2009-06-10 2011-02-16 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
WO2011024987A1 (ja) 2009-08-31 2011-03-03 塩野義製薬株式会社 芳香族縮合へテロ環誘導体およびそれらを含有する医薬組成物
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
WO2011054851A1 (en) 2009-11-05 2011-05-12 Glaxosmithkline Llc Novel process
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
HUE026967T2 (en) 2009-11-05 2016-07-28 Glaxosmithkline Llc Benzodiazepine Bromodomain inhibitor
DK2722334T3 (en) 2009-11-05 2016-03-07 Glaxosmithkline Llc benzodiazepine bromdomæneinhibitor
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
BR112012026641A2 (pt) 2010-04-23 2016-07-12 Kineta Inc compostos antivirais
JP5913292B2 (ja) 2010-05-14 2016-04-27 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 代謝を調節する組成物および方法
DK2571503T3 (en) 2010-05-14 2015-04-20 Dana Farber Cancer Inst Inc COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS
CA2799403C (en) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
US9301962B2 (en) 2010-05-14 2016-04-05 Baylor College Of Medicine Male contraceptive compositions and methods of use
ES2526671T3 (es) 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
BR112013020329A2 (pt) 2011-02-09 2016-08-02 Hoffmann La Roche compostos heterocíclicos como inibidores da pi3-quinase
CA2828212A1 (en) 2011-02-23 2012-08-30 Shiraz Mujtaba Inhibitors of bromodomains as modulators of gene expression
CA2825966A1 (en) 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use
GB201106799D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201106750D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201106743D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201107325D0 (en) 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2706852B1 (en) 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012178208A2 (en) 2011-06-24 2012-12-27 The Trustees Of The Stevens Institute Of Technology Selective inhibitors of histone deacetylase isoform 6 and methods thereof
JP2013010719A (ja) 2011-06-30 2013-01-17 Dainippon Sumitomo Pharma Co Ltd ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
CA2843643A1 (en) 2011-07-29 2013-02-07 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hiv
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013033270A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same
WO2013033269A1 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
SI2751083T1 (en) 2011-08-31 2018-04-30 Otsuka Pharmaceutical Co., Ltd. Quinolone compound
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
ES2632443T3 (es) 2011-09-22 2017-09-13 Viiv Healthcare Uk Limited Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH
CN103857391B (zh) 2011-09-30 2016-06-08 沈阳蓝桑医药生物技术研发有限公司 含有瑞利格内酯的药物组合物及其应用
WO2013060636A1 (en) 2011-10-25 2013-05-02 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2012330885B2 (en) 2011-11-01 2016-10-06 Resverlogix Corp. Oral immediate release formulations for substituted quinazolinones
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2013148197A1 (en) 2012-03-28 2013-10-03 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281399A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281396A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281398A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
WO2013155695A1 (en) 2012-04-20 2013-10-24 Abbott Laboratories Isoindolone derivatives
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
US9624244B2 (en) 2012-06-06 2017-04-18 Constellation Pharmaceuticals, Inc. Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
SG11201408324QA (en) 2012-06-12 2015-01-29 Abbvie Inc Pyridinone and pyridazinone derivatives
BR112014032105A2 (pt) 2012-06-25 2017-08-01 Oncoethix Sa método para o tratamento de câncer
US9610332B2 (en) 2012-07-18 2017-04-04 Massachusetts Institute Of Technology Compositions and methods for modulating BRD4 bioactivity
CA2880578A1 (en) 2012-08-16 2014-02-20 Glaxosmithkline Llc Benzodiazepines for treating small cell lung cancer
WO2014026997A1 (de) 2012-08-16 2014-02-20 Bayer Pharma Aktiengesellschaft 2,3-benzodiazepine
HK1208448A1 (en) 2012-09-28 2016-03-04 Bayer Pharma Aktiengesellschaft Bet protein-inhibiting 5-aryl triazole azepines
KR20150100613A (ko) 2012-09-28 2015-09-02 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 함유하는 약제학적 제제
WO2014074775A1 (en) 2012-11-09 2014-05-15 Jacobus Pharmaceutical Company, Inc. Heteroaryl derivatives and uses thereof
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
ES2625945T3 (es) 2012-11-14 2017-07-21 Glaxosmithkline Llc Tieno[3,2-c]piridin-4(5H)-onas como inhibidores de bet
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014095775A1 (de) 2012-12-20 2014-06-26 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische dihydrochinoxalinone
EP2935260A1 (de) 2012-12-20 2015-10-28 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische dihydropyridopyrazinone
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
WO2014128655A1 (en) 2013-02-25 2014-08-28 Aurigene Discovery Technologies Limited Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors
US10053454B2 (en) 2013-02-27 2018-08-21 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
AU2014249192B2 (en) 2013-03-11 2017-12-21 The Regents Of The University Of Michigan BET bromodomain inhibitors and therapeutic methods using the same
JP2016512524A (ja) 2013-03-11 2016-04-28 アッヴィ・インコーポレイテッド ブロモドメイン阻害剤
US8980879B2 (en) 2013-03-11 2015-03-17 Abbvie Inc. Bromodomain inhibitors
AU2014248663A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Dihydro-pyrrolopyridinone bromodomain inhibitors
JP6419735B2 (ja) 2013-03-12 2018-11-07 アッヴィ・インコーポレイテッド 四環系ブロモドメイン阻害剤
CA2905426A1 (en) 2013-03-12 2014-10-09 Abbvie Inc. Pyrrole amide inhibitors
US9695179B2 (en) 2013-03-14 2017-07-04 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
KR20150128842A (ko) 2013-03-14 2015-11-18 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 브로모도메인 억제제로서의 퓨로피리딘
WO2014159392A1 (en) 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
SMT201900009T1 (it) 2013-03-14 2019-02-28 Glaxosmithkline Ip No 2 Ltd Derivati 1-acil-4-ammino-1,2,3,4-tetraidrochinolinici 2,3-disostituiti e loro uso come inibitori del bromodominio
KR102244719B1 (ko) 2013-03-15 2021-04-26 플렉시콘 인코퍼레이티드 헤테로시클릭 화합물 및 그의 용도
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
WO2014152029A2 (en) 2013-03-15 2014-09-25 Epigenetix, Inc. Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
US9199988B2 (en) 2013-03-27 2015-12-01 Boehringer Ingelheim International Gmbh Dihydroquinazolinone analogues
EP2978757B1 (en) 2013-03-27 2017-02-08 Boehringer Ingelheim International GmbH Indolinone analogues as brd4 inhibitors
TWI530499B (zh) 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
EP2996689A1 (en) 2013-04-17 2016-03-23 Albert-Ludwigs-Universität Freiburg Compounds for use as bromodomain inhibitors
HK1217484A1 (zh) 2013-04-26 2017-01-13 百济神州有限公司 取代的5-(3，5-二甲基异恶唑-4-基)二氢吲哚-2-酮类衍生物
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
EA029312B1 (ru) 2013-05-27 2018-03-30 Новартис Аг Производные имидазопирролидинона и их применение при лечении заболеваний
KR20160012197A (ko) 2013-05-28 2016-02-02 노파르티스 아게 피라졸로-피롤리딘-4-온 유도체 및 질환의 치료에서의 그의 용도
MX2015016421A (es) 2013-05-28 2016-03-03 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
CA2915419A1 (en) 2013-06-17 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted phenyl-2,3-benzodiazepines
ITMI20130991A1 (it) 2013-06-17 2014-12-18 Industrie De Nora Spa Sistema per la misurazione di correnti presenti sugli elettrodi in celle elettrolitiche interconnesse.
WO2015004533A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
PL3010503T3 (pl) 2013-06-21 2020-08-24 Zenith Epigenetics Ltd. Nowe bicykliczne inhibitory bromodomen
AR096758A1 (es) 2013-06-28 2016-02-03 Abbvie Inc Inhibidores cristalinos de bromodominios
JP2016525503A (ja) 2013-06-28 2016-08-25 アッヴィ・インコーポレイテッド ブロモドメイン阻害剤
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
PL3022191T3 (pl) 2013-07-16 2017-08-31 Basf Se Chwastobójcze azyny
CA2918910A1 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
KR101672096B1 (ko) 2013-09-30 2016-11-02 주식회사 엘지화학 헤테로환 화합물 및 이를 포함하는 유기 발광 소자
HRP20200341T1 (hr) 2013-10-18 2020-06-12 Celgene Quanticel Research, Inc. Bromodomenski (bet) inhibitori
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US20150148372A1 (en) 2013-11-26 2015-05-28 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9428514B2 (en) 2013-12-09 2016-08-30 Abbvie Inc. Bromodomain inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US9822107B2 (en) 2013-12-20 2017-11-21 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
SG11201604916YA (en) 2014-01-09 2016-07-28 Orion Corp Bicyclic heterocyclic derivatives as bromodomain inhibitors
CA2940554A1 (en) 2014-02-28 2015-09-03 The Regents Of The University Of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
KR102702503B1 (ko) 2014-04-23 2024-09-05 인사이트 홀딩스 코포레이션 BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
CR20160545A (es) 2014-04-23 2017-03-31 Basf Se Compuestos de diaminotriazina como herbicidas
KR102349237B1 (ko) 2014-04-23 2022-01-07 다케다 야쿠힌 고교 가부시키가이샤 알츠하이머 병의 치료를 위한 콜린작동성 무스카린 ｍ１ 수용체 양성 알로스테릭 조절인자 활성을 갖는 이소인돌린-1-온 유도체
JP2017514909A (ja) 2014-05-02 2017-06-08 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を用いる急性骨髄性白血病及び／又は急性リンパ芽球性白血病の治療方法
WO2015168555A1 (en) 2014-05-02 2015-11-05 Oncoethix Sa Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds
WO2015169953A1 (en) 2014-05-08 2015-11-12 Oncoethix Gmbh Method of treating glioma using thienotriazolodiazepine compounds
MX2016014574A (es) 2014-05-08 2017-02-23 Oncoethix Gmbh El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo.
WO2015184257A2 (en) 2014-05-30 2015-12-03 Icahn School Of Medicine At Mount Sinai Small molecule transcription modulators of bromodomains
LT3157928T (lt) 2014-06-20 2019-05-27 Constellation Pharmaceuticals, Inc. 2-((4s)-6-(4-chlorfenil)-1-metil-4h-benzo[c]iizoksazolo[4,5-e]azepin-4-il)acetamido kristalinės formos
WO2016044130A1 (en) 2014-09-15 2016-03-24 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
CN110511209B (zh) 2014-10-24 2022-07-05 百时美施贵宝公司 可用作激酶抑制剂的吲哚甲酰胺化合物
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
WO2016123709A1 (en) 2015-02-03 2016-08-11 Trillium Therapeutics Inc. Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins
WO2016186453A1 (en) 2015-05-20 2016-11-24 Kainos Medicine, Inc. Quinoline derivatives as bromodomain inhibitors
MA43120A (fr) 2015-05-29 2018-09-05 Shionogi & Co Dérivé tricyclique contenant de l'azote présentant une activité inhibitrice de la réplication du vih
CN105039258B (zh) 2015-07-03 2018-04-17 北京大学 将非神经元细胞重编程为神经元样细胞的方法和组合物
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CN105254635A (zh) 2015-10-30 2016-01-20 中国药科大学 一类咪唑并吡嗪类化合物及其药物组合物和用途
US20170127985A1 (en) 2015-11-11 2017-05-11 Medtronic Minimed, Inc. Sensor set
WO2017103670A1 (en) 2015-12-14 2017-06-22 Zenith Epigenetics Lid. 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors
US10519151B2 (en) 2016-01-28 2019-12-31 Neomed Institute Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
WO2017133681A1 (zh) 2016-02-05 2017-08-10 正大天晴药业集团股份有限公司 溴区结构域蛋白抑制剂的三环类化合物及其制备、药物组合物和用途
PH12021551886A1 (en) 2016-06-20 2023-07-17 Incyte Corp Crystalline solid forms of a bet inhibitor
CN108069958A (zh) 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用

Also Published As

Publication number Publication date
EP4218766A1 (en) 2023-08-02
NZ763740A (en) 2023-06-30
CR20160542A (es) 2017-04-25
US20180312506A1 (en) 2018-11-01
US10472358B2 (en) 2019-11-12
US11702416B2 (en) 2023-07-18
RS60139B1 (sr) 2020-05-29
AU2021200450A1 (en) 2021-02-25
PT3134403T (pt) 2020-05-18
EA034972B1 (ru) 2020-04-13
EP3134403A1 (en) 2017-03-01
PH12016502115B1 (en) 2020-07-01
US20200377502A1 (en) 2020-12-03
US9540368B2 (en) 2017-01-10
KR20160145796A (ko) 2016-12-20
NZ725930A (en) 2023-04-28
AU2015249810A1 (en) 2015-10-29
WO2015164480A1 (en) 2015-10-29
AU2015249810B2 (en) 2019-04-18
US20200048251A1 (en) 2020-02-13
CN106414442A (zh) 2017-02-15
DK3674302T3 (da) 2023-04-03
US12227502B2 (en) 2025-02-18
ES2942723T3 (es) 2023-06-06
SI3134403T1 (sl) 2020-07-31
EP3134403B1 (en) 2020-02-12
PH12016502115A1 (en) 2017-01-16
EA202090371A1 (ru) 2020-06-30
FI3674302T3 (fi) 2023-04-27
AR100160A1 (es) 2016-09-14
HUE049627T2 (hu) 2020-09-28
IL273049B (en) 2021-03-25
JP6745390B2 (ja) 2020-08-26
IL248415A0 (en) 2016-11-30
TW201938559A (zh) 2019-10-01
LT3674302T (lt) 2023-06-12
PL3674302T3 (pl) 2023-07-24
NZ763737A (en) 2023-04-28
UA119870C2 (uk) 2019-08-27
US9957268B2 (en) 2018-05-01
KR20240134245A (ko) 2024-09-06
SI3674302T1 (sl) 2023-07-31
AU2015249810A8 (en) 2016-11-24
KR20220113552A (ko) 2022-08-12
US10781209B2 (en) 2020-09-22
LT3134403T (lt) 2020-05-11
TWI672301B (zh) 2019-09-21
MA39985B1 (fr) 2020-03-31
AU2021200450B2 (en) 2022-08-04
CA2946731A1 (en) 2015-10-29
TW201625607A (zh) 2016-07-16
CY1122948T1 (el) 2021-10-29
US11059821B2 (en) 2021-07-13
PE20170144A1 (es) 2017-03-16
AU2019205984A1 (en) 2019-08-01
PL3134403T3 (pl) 2020-07-13
EA039678B1 (ru) 2022-02-24
MX2016013851A (es) 2017-07-14
US20250145621A1 (en) 2025-05-08
US20210300925A1 (en) 2021-09-30
MY207899A (en) 2025-03-27
KR102702503B1 (ko) 2024-09-05
ES2784846T3 (es) 2020-10-01
SG11201608843TA (en) 2016-11-29
ME03763B (me) 2021-04-20
EP3674302B1 (en) 2023-03-01
SG10201809353TA (en) 2018-11-29
ECSP16088983A (es) 2017-05-31
AU2019205984B2 (en) 2020-10-29
EA201692134A1 (ru) 2017-02-28
BR112016024626B1 (pt) 2023-03-21
SMT202000133T1 (it) 2020-05-08
US20240002381A1 (en) 2024-01-04
PT3674302T (pt) 2023-05-10
EP3674302A1 (en) 2020-07-01
IL273049A (en) 2020-04-30
JP6572237B2 (ja) 2019-09-04
DK3134403T3 (en) 2020-03-09
KR102430144B1 (ko) 2022-08-08
JP2019206584A (ja) 2019-12-05
MY198727A (en) 2023-09-20
BR112016024626A2 (pt) 2017-08-15
RS64231B1 (sr) 2023-06-30
CA2946731C (en) 2022-06-07
SMT202300154T1 (it) 2023-07-20
TWI735002B (zh) 2021-08-01
CN106414442B (zh) 2019-03-15
ZA202101718B (en) 2025-12-17
CL2016002681A1 (es) 2017-02-03
CY1126052T1 (el) 2023-11-15
MX2020011035A (es) 2020-10-28
US20170158689A1 (en) 2017-06-08
CR20200231A (es) 2020-09-11
MX376174B (es) 2025-03-07
MY180775A (en) 2020-12-09
HRP20230340T1 (hr) 2023-06-09
IL248415B (en) 2020-03-31
JP2017513879A (ja) 2017-06-01
HRP20200564T1 (hr) 2020-06-26
BR112016024626A8 (pt) 2021-07-20
IL281263A (en) 2021-04-29
US20150307493A1 (en) 2015-10-29
IL281263B (en) 2021-09-30

Similar Documents

Publication Publication Date Title
IL281263B (en) 1h - pyrrolo[2,3-c]pyridine-7(6h)-one and pyrazolo[3,4-c]pyridine-7 (6h)-one as inhibitors of beta proteins
ZA201802976B (en) N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
IL240010B (en) Sulfonyl-2-(1h-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide compounds for the treatment of cancer and autoimmune diseases
IL252578B (en) History of 1h- pyrazolo (3.4-c) [5.1] naphthyridine 4-(5h)-one and pharmaceutical preparations containing them
PL2970260T3 (pl) Pochodne imidazo[4,5-c]pirydyny i pirolo[2,3-c]pirydyny jako inhibitory ssao
IL262257B (en) 1, 5, -dihydro-4h -pyrazolo[3, 4-d]pyrimidin-4-one and 1, 5, -dihydro-4h -pyrazolo[3, 4-c]pyridin-4-one as pde1 inhibitors
GB201802644D0 (en) Monocyclic,thieno, pyrido and pyrrolo pyrimidine compounds and methods of use and manufacture of the same
IL249307A0 (en) History of h2-pyrazolo[3,4-c]quinolin-3(h5)-one and their use